This is a table of adjective/noun combinations and their frequencies from sentences in your study carrel. Use it to search & browse the list to learn more about your study carrel.
adjective | noun | frequency |
---|---|---|
- | cov-2 | 4875 |
- | cov | 2142 |
- | rbd | 461 |
human | ace2 | 336 |
- | protein | 282 |
novel | coronavirus | 237 |
monoclonal | antibodies | 203 |
- | ace2 | 177 |
monoclonal | antibody | 169 |
immune | response | 164 |
immune | responses | 161 |
- | sars | 160 |
- | cell | 135 |
human | coronavirus | 117 |
viral | infection | 96 |
- | s | 93 |
- | coronavirus | 90 |
specific | antibodies | 82 |
viral | spike | 71 |
human | cells | 70 |
recombinant | protein | 60 |
human | receptor | 60 |
- | spike | 55 |
- | domain | 49 |
structural | proteins | 49 |
specific | antibody | 46 |
- | receptor | 41 |
recombinant | rbd | 41 |
viral | infections | 38 |
- | infection | 36 |
single | domain | 35 |
human | antibody | 33 |
structural | studies | 32 |
human | cell | 31 |
humans | . | 29 |
viral | proteins | 29 |
recombinant | proteins | 28 |
available | . | 27 |
recombinant | mers | 24 |
recombinant | sars | 24 |
respiratory | coronavirus | 24 |
human | antibodies | 23 |
therapeutic | antibodies | 23 |
other | viruses | 22 |
convalescent | patients | 21 |
therapeutics | . | 21 |
potent | sars | 21 |
immune | cells | 20 |
viral | protein | 20 |
viral | s | 20 |
human | sars | 19 |
viral | rbd | 19 |
- | residue | 17 |
potent | binding | 16 |
other | studies | 15 |
respiratory | infections | 14 |
- | binding | 14 |
- | virus | 14 |
- | antibody | 13 |
recombinant | receptor | 13 |
recombinant | s | 13 |
viral | receptor | 13 |
convalescent | sars | 12 |
human | proteins | 12 |
other | . | 12 |
other | sars | 11 |
structural | protein | 11 |
different | spike | 11 |
other | antibodies | 11 |
monoclonal | sars | 11 |
recombinant | ace2 | 10 |
- | structure | 9 |
potential | . | 9 |
specific | binding | 9 |
specific | residues | 9 |
severe | infection | 8 |
potential | vaccine | 8 |
other | coronavirus | 8 |
human | interaction | 8 |
different | mers | 8 |
positive | patients | 7 |
viral | cell | 7 |
therapeutic | antibody | 7 |
specific | interaction | 7 |
severe | patients | 7 |
respiratory | viruses | 7 |
recombinant | spike | 7 |
positive | sars | 7 |
positive | . | 7 |
other | receptors | 7 |
novel | sars | 7 |
lower | antibody | 7 |
high | antibody | 7 |
different | sars | 7 |
different | domains | 7 |
- | cells | 7 |
novel | rbd | 6 |
specific | residue | 6 |
specific | rbd | 6 |
single | cell | 6 |
severe | sars | 6 |
severe | infections | 6 |
others | . | 6 |
other | rbd | 6 |
higher | antibody | 6 |
different | coronavirus | 6 |
convalescent | patient | 6 |
acute | sars | 6 |
- | response | 6 |
- | mers | 6 |
highest | binding | 6 |
potential | antibody | 5 |
same | receptor | 5 |
respiratory | virus | 5 |
same | ace2 | 5 |
same | cell | 5 |
viral | vaccines | 5 |
similar | binding | 5 |
specific | protein | 5 |
viral | antibodies | 5 |
recombinant | antibody | 5 |
human | protein | 5 |
other | virus | 5 |
novel | receptor | 5 |
molecular | structures | 5 |
molecular | interactions | 5 |
human | infections | 5 |
human | infection | 5 |
higher | binding | 5 |
high | binding | 5 |
- | proteins | 5 |
other | interactions | 5 |
single | antibody | 4 |
recombinant | vaccines | 4 |
respiratory | infection | 4 |
same | . | 4 |
same | protein | 4 |
viral | binding | 4 |
single | protein | 4 |
specific | . | 4 |
specific | cell | 4 |
such | antibodies | 4 |
potent | antibody | 4 |
recombinant | vaccine | 4 |
- | structured | 4 |
positive | cells | 4 |
monoclonal | cells | 4 |
molecular | interaction | 4 |
lower | protein | 4 |
low | protein | 4 |
different | studies | 4 |
different | antibody | 4 |
different | ace2 | 4 |
clinical | response | 4 |
available | sars | 4 |
- | interaction | 4 |
novel | virus | 4 |
recombinant | coronavirus | 3 |
similar | . | 3 |
recombinant | viruses | 3 |
positive | residues | 3 |
recombinant | antibodies | 3 |
potential | sars | 3 |
potential | binding | 3 |
potent | antibodies | 3 |
similar | rbd | 3 |
similar | protein | 3 |
specific | response | 3 |
similar | structure | 3 |
single | cells | 3 |
single | patient | 3 |
single | rbd | 3 |
specific | sars | 3 |
such | interaction | 3 |
such | interactions | 3 |
therapeutic | . | 3 |
viral | response | 3 |
other | protein | 3 |
other | residues | 3 |
same | binding | 3 |
other | patients | 3 |
high | . | 3 |
novel | viruses | 3 |
- | antibodies | 3 |
- | residues | 3 |
acute | infection | 3 |
anti | sars | 3 |
different | antibodies | 3 |
different | cell | 3 |
different | protein | 3 |
different | rbd | 3 |
different | s | 3 |
clinical | studies | 3 |
high | infection | 3 |
human | patients | 3 |
human | virus | 3 |
humans | sars | 3 |
immune | cell | 3 |
low | . | 3 |
lower | interaction | 3 |
molecular | structure | 3 |
monoclonal | rbd | 3 |
higher | rbd | 3 |
potential | mers | 2 |
same | structure | 2 |
same | residues | 2 |
same | residue | 2 |
same | domain | 2 |
recombinant | virus | 2 |
other | spike | 2 |
potent | mers | 2 |
potent | ace2 | 2 |
positive | patient | 2 |
positive | binding | 2 |
single | residue | 2 |
similar | infection | 2 |
viral | residues | 2 |
specific | ace2 | 2 |
specific | receptor | 2 |
specific | receptors | 2 |
structural | domain | 2 |
structural | figures | 2 |
structural | interaction | 2 |
structural | interactions | 2 |
such | studies | 2 |
such | study | 2 |
such | vaccines | 2 |
therapeutic | vaccines | 2 |
other | proteins | 2 |
viral | vaccine | 2 |
other | s | 2 |
specific | responses | 2 |
other | domains | 2 |
high | receptor | 2 |
novel | vaccine | 2 |
- | . | 2 |
- | domains | 2 |
- | receptors | 2 |
- | structures | 2 |
available | mers | 2 |
clinical | study | 2 |
convalescent | antibody | 2 |
different | binding | 2 |
different | patients | 2 |
different | receptors | 2 |
high | ace2 | 2 |
different | interaction | 2 |
high | sars | 2 |
human | vaccine | 2 |
novel | cell | 2 |
higher | . | 2 |
novel | . | 2 |
non | s | 2 |
lower | . | 2 |
immune | antibodies | 2 |
human | studies | 2 |
human | residues | 2 |
human | . | 2 |
higher | receptor | 2 |
novel | mers | 2 |
similar | antibody | 1 |
same | antibody | 1 |
same | infection | 1 |
same | sars | 1 |
same | study | 1 |
similar | structures | 1 |
similar | interaction | 1 |
similar | residues | 1 |
similar | responses | 1 |
similar | s | 1 |
potential | virus | 1 |
similar | studies | 1 |
same | antibodies | 1 |
other | structure | 1 |
potential | vaccines | 1 |
potential | residues | 1 |
potential | receptor | 1 |
potent | interaction | 1 |
positives | . | 1 |
positive | spikes | 1 |
positive | responses | 1 |
positive | rbd | 1 |
positive | interactions | 1 |
other | vaccines | 1 |
other | vaccine | 1 |
other | structures | 1 |
single | interaction | 1 |
other | patient | 1 |
single | ace2 | 1 |
specific | virus | 1 |
single | interactions | 1 |
structural | spike | 1 |
other | infections | 1 |
viral | spikes | 1 |
viral | receptors | 1 |
viral | antibody | 1 |
therapeutic | responses | 1 |
therapeutic | proteins | 1 |
such | virus | 1 |
such | structures | 1 |
such | sars | 1 |
such | protein | 1 |
such | . | 1 |
structural | study | 1 |
structural | sars | 1 |
single | receptor | 1 |
structural | residues | 1 |
structural | domains | 1 |
specific | vaccine | 1 |
specific | structure | 1 |
specific | s | 1 |
specific | infection | 1 |
specific | coronavirus | 1 |
single | viruses | 1 |
single | virus | 1 |
single | vaccine | 1 |
single | spike | 1 |
single | s | 1 |
other | interaction | 1 |
high | protein | 1 |
other | antibody | 1 |
different | domain | 1 |
higher | residue | 1 |
higher | protein | 1 |
higher | mers | 1 |
higher | infection | 1 |
higher | cell | 1 |
high | virus | 1 |
high | s | 1 |
different | virus | 1 |
different | vaccine | 1 |
different | receptor | 1 |
different | proteins | 1 |
different | patient | 1 |
convalescent | . | 1 |
higher | responses | 1 |
clinical | virus | 1 |
available | structures | 1 |
available | rbd | 1 |
available | antibody | 1 |
anti | spike | 1 |
anti | mers | 1 |
acute | infections | 1 |
- | vaccine | 1 |
- | patients | 1 |
- | patient | 1 |
- | interactions | 1 |
- | infections | 1 |
higher | response | 1 |
higher | s | 1 |
novel | residues | 1 |
low | binding | 1 |
novel | interactions | 1 |
novel | domain | 1 |
novel | ace2 | 1 |
monoclonal | cell | 1 |
molecular | studies | 1 |
molecular | responses | 1 |
molecular | figures | 1 |
lower | s | 1 |
lower | responses | 1 |
low | sars | 1 |
low | rbd | 1 |
low | interaction | 1 |
low | antibodies | 1 |
higher | spike | 1 |
immune | receptors | 1 |
immune | receptor | 1 |
immune | antibody | 1 |
humans | mers | 1 |
human | viruses | 1 |
human | vaccines | 1 |
human | receptors | 1 |
human | mers | 1 |
human | domain | 1 |
highest | rbd | 1 |
highest | antibody | 1 |
higher | virus | 1 |
viral | structure | 1 |